Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

TAG:

human genome sequencing

At Executive War College 2016, Two Big Lab Market Trends

CEO SUMMARY: What happens when 100 lab experts interact with an audience of more than 850 lab administrators, pathologists, and IVD executives from across the United States and seven other nations? A consensus of sorts emerges and during this 2016 edition of the Executive War College on L…

Read More



Understanding the Future Of Laboratory Medicine

CEO SUMMARY: Healthcare’s transformation is now far enough along that most clinical labs and pathology groups are either feeling the financial pain or are excitedly developing ways to deliver more value from lab testing services. On April 26-27, at the 21st annual …

Read More



Whole Genome Sequencing Is Poised for Clinical Use

CEO SUMMARY: Pathologists and clinical lab managers interested in following the advances in use of whole human genome sequencing for clinical purposes should follow the money. Within weeks of obtaining FDA clearance for its MiSeqDx system and reagents, Illumina had inked major agreements …

Read More



2013’s Top Ten Lab Stories Point to Tougher Times

CEO SUMMARY: For 2013, the big story was money—or, more accurately, less money for providers. This was not limited to clinical labs and pathology groups, but was equally true of hospitals and physicians. In THE DARK REPORT’S annual lookback at the year’s 10…

Read More



April 23, 2012 “Intelligence: Late Breaking Lab News”

“Innovator of the Year” honors were recently bestowed on Robin Felder, Ph.D., who is Professor of Pathology and Associate Director of Clinical Chemistry at the University of Virginia School of Medicine in Charlottesville. Felder was selected as the winner of the 2012 Edlich-Hen…

Read More



April 2, 2012 “Intelligence: Late Breaking Lab News”

Like a tenacious bulldog, Roche Holding AG continues its determined effort to acquire Illumina, Inc., the company that makes gene sequencing systems. Last week, Roche increased its offer from $44.50 per share to $51 per share for Illumina stock. That raises the price…

Read More



Considering Full versus Partial Adoption of Digital Pathology

CEO SUMMARY: Digital pathology is considered to be one of the more disruptive technologies now finding acceptance in anatomic pathology. Since founding Aperio Technologies, Inc., of Vista, California, in 1999, President Dirk G. Soenksen, M.S., M.B.A., has been in the forefront of this imp…

Read More



May 23, 2011 “Intelligence: Late Breaking Lab News”

The first sequencing of the whole human genome back in 2000 unleashed a tidal wave of research and development. Recently, Fast Company Magazine quantified the dollar impact of the Human Genome Project and now says it totals $800 billion! Their reporter communicates this so succinctly that TH…

Read More



Our Top Ten Lab Stories Highlight Major Changes

CEO SUMMARY: What makes 2010 a watershed year for the laboratory testing industry is enactment of the 2,700-page Patient Protection and Affordable Care Act (PPACA). Even if parts of this bill are repealed, the remaining parts of the massive legislation will trigger major changes …

Read More



Whole Genome Sequencing: Is It Ready for Prime Time?

CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagn…

Read More



How Much Laboratory Business Intelligence Have You Missed?

Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!

Sign up for TDR Insider

Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.

;